By Connor Hart
Shares of Silexion Therapeutics surged after the company released what it called promising preclinical data for its treatment of pancreatic cancer.
The stock jumped 68%, to $2.61, in after-hours trading Wednesday. Shares ended the regular session 12% lower, at $1.56, putting them down more than 98% in the last year.
The biotech company said its proprietary second-generation siRNA candidate, SIL-204, demonstrated synergistic efficacy in combination with components of first-line chemotherapy for pancreatic cancer.
Additional preclinical data show that the drug exhibits synergistic activity with 5-fluorouracil and irinotecan--two main components commonly used in pancreatic-cancer treatments--when tested in human pancreatic tumor cell lines harboring KRAS G12D mutations, which is the most common mutation in pancreatic cancer, the company said.
Moving forward, Silexion said it will continue developing SIL-204. It plans to initiate toxicology studies with the drug within the upcoming months, as well as advance it into Phase 2/3 clinical trials in the first half of 2026.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
January 15, 2025 18:05 ET (23:05 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.